Population‐specific single‐nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans. Issue 5 (21st June 2016)

• Record Type: Journal Article
• Authors: Daneshjou, Roxana; Cavallari, Larisa H.; Weeke, Peter E.; Karczewski, Konrad J.; Drozda, Katarzyna; Perera, Minoli A.; Johnson, Julie A.; Klein, Teri E.; Bustamante, Carlos D.; Roden, Dan M.; Shaffer, Christian; Denny, Joshua C.; Zehnder, James L.; Altman, Russ B.
• Is Part Of: Molecular genetics & genomic medicine. Volume 4:Issue 5(2016)
• Page Start: 513
• Page End: 520
• Publication Date: 2016-06-21
• Subjects: African American -- hypercoagulability -- pulmonary embolism -- venous thromboembolism; Medical genetics -- Periodicals; Genomics -- Periodicals; 616.042
• DOI: 10.1002/mgg3.226
• Languages: English
• ISSNs: 2324-9269

Abstract

Abstract: Introduction: African Americans have a higher incidence of venous thromboembolism (VTE) than European descent individuals. However, the typical genetic risk factors in populations of European descent are nearly absent in African Americans, and population‐specific genetic factors influencing the higher VTE rate are not well characterized. Methods: We performed a candidate gene analysis on an exome‐sequenced African American family with recurrent VTE and identified a variant in Protein S ( PROS1 ) V510M (rs138925964). We assessed the population impact of PROS1 V510M using a multicenter African American cohort of 306 cases with VTE compared to 370 controls. Additionally, we compared our case cohort to a background population cohort of 2203 African Americans in the NHLBI GO Exome Sequencing Project (ESP). Results: In the African American family with recurrent VTE, we found prior laboratories for our cases indicating low free Protein S levels, providing functional support for PROS1 V510M as the causative mutation. Additionally, this variant was significantly enriched in the VTE cases of our multicenter case–control study (Fisher's Exact Test, P = 0.0041, OR = 4.62, 95% CI: 1.51–15.20; allele frequencies – cases: 2.45%, controls: 0.54%). Similarly, PROS1 V510M was also enriched in our VTE case cohort compared to African Americans in the ESP cohort (Fisher's Exact Test, P = 0.010, OR = 2.28, 95% CI: 1.26–4.10). Conclusions: We found a variant, PROS1 V510M, in an African American family with VTE and clinical laboratory abnormalities in Protein S. Additionally, we found that this variant conferred increased risk of VTE in a case–control study of African Americans. In the ESP cohort, the variant is nearly absent in ESP European descent subjects ( n = 3, allele frequency: 0.03%). Additionally, in 1000 Genomes Phase 3 data, the variant only appears in African descent populations. Thus, PROS1 V510M is a population‐specific genetic risk factor for VTE in African Americans. Abstract : We identified a novel association between a mutation in Protein S and venous thromboembolism in an African American family. We then demonstrated that this mutation is a population‐specific risk factor for venous thromboembolism in African Americans.